VMP-like sequences of pathogenic Borrelia species and strains

Details VMP-like sequences of pathogenic Borrelia species and strains VMP-like sequences of pathogenic Borrelia species and strains

2010-12-07

2011-12-13

Swartz, Rodney P. (Department: 1645)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C424S184100, C424S185100, C424S190100, C424S200100, C424S234100

Reexamination Certificate

active

08076470

ABSTRACT:
The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenicBorrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.

REFERENCES:
patent: 4554101 (1985-11-01), Hopp
patent: 4578770 (1986-03-01), Mitani
patent: 4596792 (1986-06-01), Vyas
patent: 4599230 (1986-07-01), Milich et al.
patent: 4599231 (1986-07-01), Milich et al.
patent: 4601903 (1986-07-01), Frasch
patent: 4608251 (1986-08-01), Mia
patent: 4721617 (1988-01-01), Johnson
patent: 4801540 (1989-01-01), Hiatt et al.
patent: 5155022 (1992-10-01), Naqui et al.
patent: 5178859 (1993-01-01), Simon et al.
patent: 5187065 (1993-02-01), Schutzer
patent: 5217872 (1993-06-01), Dorward et al.
patent: 5217874 (1993-06-01), Guadagno et al.
patent: 5246844 (1993-09-01), Norris et al.
patent: 5279938 (1994-01-01), Rosa
patent: 5283175 (1994-02-01), Weaver et al.
patent: 5304718 (1994-04-01), Ward et al.
patent: 5324630 (1994-06-01), LeFebvre et al.
patent: 5385826 (1995-01-01), Schell et al.
patent: 5434077 (1995-07-01), Simon et al.
patent: 5436000 (1995-07-01), Barbour et al.
patent: 5571718 (1996-11-01), Dunn et al.
patent: 6437116 (2002-08-01), Norris et al.
patent: 6475492 (2002-11-01), Philipp et al.
patent: 6610301 (2003-08-01), Motz et al.
patent: 6660274 (2003-12-01), Philipp
patent: 6719983 (2004-04-01), Norris et al.
patent: 6740744 (2004-05-01), Norris et al.
patent: 6878816 (2005-04-01), Norris et al.
patent: 7135176 (2006-11-01), Norris et al.
patent: 2007/0117970 (2007-05-01), Norris et al.
patent: WO 91/13630 (1991-09-01), None
patent: WO 97/31123 (1997-08-01), None
patent: WO 99/00413 (1999-01-01), None
patent: WO99/00413 (1999-01-01), None
patent: WO 00/65064 (2000-11-01), None
Balmelii and Piffatetti, “Analysis of the genetic polymorphism ofBorrelia burgdorferisensu lato by multilocus enzyme electrophoresis,”Int. J. Syst. Bacteriol., 46:167-172, 1996.
Barbour and Garon, “Linear plasmids of the bacteriumBorrelia burdorferihave covalently closed ends,”Science, 237:409-411, 1987.
Barbour et al., “Structural analysis of the variable major proteins ofBorrelia hermsii,” J. Exp. Med., 158:2127-2140, 1983.
Barbour et al., “Tandem insertion sequence-like elements define the expression site for variable antigen genes ofBorrelia hermsii,” Infect. Immun., 59:390-397, 1991.
Barbour et al., “Variable antigen genes of the relapsing fever agentBorrelia hermsiiare activated by promoter addition,”Mol. Microbiol., 5:489-493, 1991.
Barbour et al., “Variable major proteins ofBorrelia hermsii,” J. Exp. Med., 156:1312-1324, 1982.
Barbour, “Immunochemical analysis of Lyme disease spirochetes,”Yale J. Biomed., 57:581-586, 1984.
Barbour, “Plasmid analysis ofBorrelia burgdorferi, the Lyme disease agent,”J. Clin. Microbiol., 26(3):475-478, 1988.
Barstad et al., “Variable major proteins ofBorrelia hermsii. Epitope mapping and partial sequence analysis of CNBr peptides,”J. Exp. Med., 161:1302-1314, 1985.
Barthold et al., “Suspectibility of laboratory rats to isolates ofBorrelia burgdorferifrom different geographic areas,”Am. J. Trop. Med. Hyg., 42:596-600, 1990.
Barthold, “Antigenic stability ofBorrelia burgdorferiduring chronic infections of immunocompetent mice,”Infect. Immun., 61:4955-4961, 1993.
Benach et al., “A murine IgM monoclonal antibody binds an antigenic determinant in outer surface protein A, an immunodominant basic protein of the lyme disease spirochete,”The Journal of Immunology, 140:265-272, 1988.
Brandt et al. “Immunogenic integral membrane proteins ofBorrelia burgdorferiare lipoproteins,”Infect. Immun., 58(4):983-991, 1990.
Burgdorfer et al., “Lyme disease, a tick-borne spirochetosis?,”Science, 216:1317-1319, 1982.
Burman et al., “The variable antigens Vmp7 and Vmp21 of the relapsing fever bacteriumBorrelia hermsiiare structurally analogous to the VSG proteins of the African trypanosome,”Molecular Mocrobiology, 4(10);1715-1726, 1990.
Cadavid et al., “Variability of a bacterial surface protein and disease expression in a possible mouse model of systemic Lyme borreliosis,”J Exp Med, 179(2):631-42, 1994.
Carroll and Gheradini, “Membrane protein variations associated with in vitro passage ofBorrelia burgdorferi,” Infect. Immun., 64:392-398, 1996.
Carter et al., “A family of surface-exposed proteins of 20 kilodaltons in the genusBorrelia,” Infect. Immun., 62:2792-2799, 1994.
Casjens et al., “Linear chromosomes of Lyme disease agent spirochetes: genetic diversity and conservation of gene order,”J. Bacteriol., 177:2769-2780, 1995.
Cluss and Boothby, “Thermoregulation of protein synthesis inBorrelia burgdorferi,” Infect. Immun., 58(4):1038-1042, 1990.
Database UniProt Online, “Complement C3 precursor (HSE-MSF) ‘Contains: Complement C3 beta chain; Complement C3 alpha chain; C3a anaphlyatoxin; Complement C3b alpha’ chain; Complement C3c fragment; Complement C3dg fragment; Complement C3g fragment; Complement C3d fragment; Complement C, isoform Short; C3f fragment!. 671 7,” Database Accession No. P01027, 1986.
Dever et al., “In vitro antimocrobial susceptibility testing ofBorrelia burgdorferi: a microdilution MIC method and time-kill studies,”J. Clin. Microbiol., 30:2692-2697, 1992.
Donelson, “Mechanisms of antigenic variation inBorrelia hermsiiand African trypanosomes,”J. Biol. Chem., 270:7783-7786, 1995.
Fawcett et al., “Detetion of antibodies to the recombinant p39 protein ofBorrelia burgdorferiusing enzyme immunoassay and immunoblotting,”J. Rheumatology, 20(4):734-738, 1993.
Fuchs et al., “Molecular analysis and expression of aBorrelia burgdorferigene encoding a 22kDa protein (pC) inE. coli,” Mol. Microbiol., 6:503-509, 1992.
GenBank Acession No. AAB09432, 1996.
GenBank Acession No. AAB17737, 1996.
GenBank Acession No. AAC45733, 1997.
Grodzicki and Steere, “Comparison of immunoblotting and indirect enzyme-linked immunosorbent assay using different antigen preparations for diagnosing early lyme disease,”J. Infect. Dis., 157(4):790-797, 1988.
Hagblom et al., “Intragenic recombination leads to pilus antigenic variation inNeisseria gonorrhoeae,” Nature, 315:156-158, 1985.
Howe et al., “A single recombinant plasmid expressing two major outer surface proteins of the lyme disease spirochete,”Science, 227:645-646, 1985.
Howe et al., “Organization of genes encoding two outer membrane proteins of the lyme disease agentBorrelia burgdorferiwithin a single transcriptional unit,”Infect. Immun., 54:207-212, 1986.
Hudson et al., “Increased expression ofBorrelia burgdorferivlsE in response to human endothelial cell membranse,”Mol. Microbiol., 41:229-239, 2001.
Hughes and Johnson, “Methylated DNA inBorreliaspecies,”J. Bacteriol., 172:6602-6604, 1990.
Hyde et al., “Detection of antigens in urine of mice and humans infected withBorrelia burgdorferi, etiologic agent of lyme disease,”Journal of Clinical Microbiology, 27(1):58-61, 1989.
Indest et al. “Analysis ofBorrelia burgdorferivlsE gene expression and recombination in the tick vector,”Infect. Immun., 69:7083-7090, 2001.
Jiang et al., “Cross-antigenicity between the major surface proteins (ospA and ospB) and other proteins ofBorrelia burgdorferi,” J. Immun., 144(1):284-289, 1990.
Johnson et al., “Infect

Affiliated with

Also associated with

Rating

VMP-like sequences of pathogenic Borrelia species and strains does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with VMP-like sequences of pathogenic Borrelia species and strains, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and VMP-like sequences of pathogenic Borrelia species and strains will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4305071